Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $6.81M worth of Aerovate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $46.5M.
The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.
2024-06-17 | 928,110 0.2418% | $1.67 | $1.55M | +20.61% | ||||
2024-06-14 | Sale | SEE REMARKS | 15,000 0.0586% | $25.03 | $375,450 | -91.92% | ||
2024-06-14 | Sale | CHIEF TECHNICAL OFFICER | 10,600 0.0413% | $25.00 | $265,000 | -91.92% | ||
2024-06-13 | Sale | CHIEF MEDICAL OFFICER | 6,000 0.0229% | $24.50 | $147,000 | -91.90% | ||
2024-05-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0136% | $21.08 | $84,332 | -89.94% | ||
2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0347% | $21.58 | $215,755 | -90.51% | ||
2024-05-02 | Sale | CHIEF TECHNICAL OFFICER | 1,981 0.007% | $21.02 | $41,631 | -89.47% | ||
2024-05-01 | Sale | CHIEF EXECUTIVE OFFICER | 11,357 0.0386% | $20.34 | $230,946 | -89.32% | ||
2024-04-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0143% | $22.38 | $89,522 | -89.21% | ||
2024-04-17 | Sale | SEE REMARKS | 6,853 0.0245% | $22.37 | $153,327 | -89.21% | ||
2024-04-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0375% | $24.70 | $246,971 | -89.63% | ||
2024-04-10 | Sale | SEE REMARKS | 7,500 0.0268% | $26.85 | $201,392 | -90.56% | ||
2024-04-09 | Sale | director | 11,882 0.0428% | $28.15 | $334,478 | -90.89% | ||
2024-04-01 | Sale | SEE REMARKS | 12,495 0.0455% | $31.23 | $390,208 | -91.50% | ||
2024-04-01 | Sale | SEE REMARKS | 3,325 0.0124% | $31.97 | $106,317 | -91.50% | ||
2024-04-01 | Sale | CHIEF TECHNICAL OFFICER | 5,300 0.0181% | $29.19 | $154,697 | -91.50% | ||
2024-04-01 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.035% | $30.00 | $300,033 | -91.50% | ||
2024-03-28 | Sale | CHIEF MEDICAL OFFICER | 9,000 0.0322% | $29.50 | $265,500 | -91.17% | ||
2024-03-27 | Sale | SEE REMARKS | 11,068 0.0393% | $27.97 | $309,519 | -90.79% | ||
2024-03-25 | Sale | SEE REMARKS | 3,432 0.0129% | $28.01 | $96,119 | -90.24% |
RA CAPITAL MANAGEMENT, L.P. | 7893678 27.3379% | $2.59 | 2 | 0 | <0.0001% | |
GRAYZEL DAVID S. | director | 14502 0.0502% | $2.59 | 1 | 1 | <0.0001% |
Gillies Hunter | CHIEF MEDICAL OFFICER | 5602 0.0194% | $2.59 | 0 | 15 | |
Eldridge George A | SEE REMARKS | 5022 0.0174% | $2.59 | 0 | 21 | |
NIVEN RALPH | CHIEF SCIENTIFIC OFFICER | 1609 0.0056% | $2.59 | 0 | 19 | |
Dake Benjamin T | SEE REMARKS | 1291 0.0045% | $2.59 | 0 | 51 | |
NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 0 0% | $2.59 | 0 | 21 | |
Verwijs Marinus | CHIEF TECHNICAL OFFICER | 0 0% | $2.59 | 0 | 8 | |
Sofinnova Venture Partners X, L.P. | 10 percent owner | 3758686 13.0173% | $2.59 | 1 | 0 | <0.0001% |
Katabi Maha | 3758686 13.0173% | $2.59 | 1 | 0 | <0.0001% | |
Atlas Venture Fund XII, L.P. | 10 percent owner | 3103879 10.7496% | $2.59 | 1 | 0 | <0.0001% |
Cormorant Asset Management, LP | 2030691 7.0328% | $2.59 | 1 | 0 | <0.0001% |
RA Capital Management, L.P. | $244.37M | 28.69 | 8.26M | 0% | +$0 | 0.25 | |
Sofinnova | $111.14M | 13.05 | 3.76M | 0% | +$0 | 0.23 | |
Tcg Crossover Management Llc | $65.09M | 7.64 | 2.2M | 0% | +$0 | 0.1 | |
Atlas Venture Life Science Advisors Llc | $60.3M | 7.08 | 2.04M | 0% | +$0 | 5.6 | |
Baker Bros Advisors LP | $49.69M | 5.83 | 1.68M | 0% | +$0 | 0.36 | |
Frazier Life Sciences Management L P | $35.63M | 4.18 | 1.2M | 0% | +$0 | 1.61 | |
Cormorant Asset Management Lp | $31.63M | 3.71 | 1.07M | -11.71% | -$4.2M | 1.47 | |
Great Point Partners | $26.25M | 3.08 | 887,690 | -14.46% | -$4.44M | 4.4 | |
Driehaus Capital Management LLC | $23.51M | 2.76 | 794,992 | -24.87% | -$7.78M | 0.23 | |
BlackRock | $20.99M | 2.46 | 709,752 | -2.43% | -$523,448.15 | <0.0001 | |
The Vanguard Group | $19.88M | 2.33 | 672,275 | +7.25% | +$1.34M | <0.0001 | |
OrbiMed | $16.72M | 1.96 | 565,374 | -25.31% | -$5.66M | 0.13 | |
Fidelity Investments | $15.89M | 1.87 | 537,530 | +<0.01% | +$1,301.08 | <0.01 | |
Eventide Asset Management | $13.17M | 1.55 | 445,500 | +3,558.24% | +$12.81M | 0.21 | |
Octagon Capital Advisors LP | $11.94M | 1.4 | 403,685 | 0% | +$0 | 0.07 | |
Point72 Asset Management | $11.82M | 1.39 | 399,824 | -9.43% | -$1.23M | 0.02 | |
Ikarian Capital LLC | $10.88M | 1.28 | 367,965 | New | +$10.88M | 1.5 | |
Geode Capital Management | $8.33M | 0.98 | 281,760 | +1.76% | +$143,875.78 | <0.01 | |
Ensign Peak Advisors Inc | $7.75M | 0.91 | 262,257 | +114.51% | +$4.14M | 0.01 | |
State Street | $6.8M | 0.8 | 229,986 | +7.46% | +$471,907.63 | <0.0001 | |
GHOST TREE CAPITAL LLC | $6.65M | 0.78 | 225,000 | +7.14% | +$443,550.00 | 0.09 | |
Woodline Partners LP | $5.91M | 0.69 | 200,000 | New | +$5.91M | 0.05 | |
Northern Trust | $2.91M | 0.34 | 98,559 | -0.97% | -$28,623.76 | <0.0001 | |
Boothbay Fund Management LLC | $2.89M | 0.34 | 97,842 | New | +$2.89M | 0.09 | |
Nantahala Capital Management Llc | $2.7M | 0.32 | 91,188 | 0% | +$0 | 0.13 | |
Millennium Management LLC | $1.85M | 0.22 | 62,555 | New | +$1.85M | <0.01 | |
Walleye Capital | $1.61M | 0.19 | 54,520 | New | +$1.61M | <0.01 | |
Eversept Partners LP | $1.6M | 0.19 | 54,150 | +7.78% | +$115,559.60 | 0.12 | |
Nan Fung Group | $1.42M | 0.17 | 47,936 | 0% | +$0 | 1.54 | |
SEB | $1.31M | 0.15 | 44,320 | -12.87% | -$193,565.16 | 0.01 | |
Alger | $1.29M | 0.15 | 43,790 | +20.05% | +$216,215.79 | 0.01 | |
Nuveen | $1.18M | 0.14 | 40,047 | 0% | +$0 | <0.0001 | |
Charles Schwab | $915,428.00 | 0.11 | 30,958 | +4.79% | +$41,871.12 | <0.0001 | |
BNY Mellon | $818,025.00 | 0.1 | 27,664 | -24.33% | -$262,995.75 | <0.0001 | |
Morgan Stanley | $777,189.00 | 0.09 | 26,283 | -25.02% | -$259,299.56 | <0.0001 | |
Shay Capital Llc | $727,067.00 | 0.09 | 24,588 | New | +$727,067.00 | 0.11 | |
Two Sigma | $677,537.00 | 0.08 | 22,913 | +134.76% | +$388,933.97 | <0.01 | |
Prelude Capital | $611,655.00 | 0.07 | 20,685 | New | +$611,655.00 | 0.05 | |
Alps Advisors Inc | $577,177.00 | 0.07 | 19,519 | +4.28% | +$23,685.58 | <0.01 | |
Parkwood LLC | $524,000.00 | 0.06 | 17,728 | +12.3% | +$57,401.17 | 0.06 | |
D. E. Shaw & Co. | $510,526.00 | 0.06 | 17,265 | New | +$510,526.00 | <0.0001 | |
Dimensional Fund Advisors | $442,279.00 | 0.05 | 14,957 | 0% | +$0 | <0.0001 | |
RhumbLine Advisers | $432,363.00 | 0.05 | 14,622 | +3.29% | +$13,749.75 | <0.0001 | |
AllianceBernstein | $387,367.00 | 0.05 | 13,100 | 0% | +$0 | <0.0001 | |
PDT Partners | $374,948.00 | 0.04 | 12,680 | New | +$374,948.00 | 0.03 | |
UBS | $332,278.00 | 0.04 | 11,237 | -8.2% | -$29,688.27 | <0.0001 | |
Jane Street Capital | $333,076.00 | 0.04 | 11,264 | -14.05% | -$54,467.86 | <0.0001 | |
Jump Financial Llc | $283,872.00 | 0.03 | 9,600 | New | +$283,872.00 | <0.01 | |
Bank of America | $263,676.00 | 0.03 | 8,917 | -60.72% | -$407,504.65 | <0.0001 | |
Barclays | $233,000.00 | 0.03 | 7,872 | -48.86% | -$222,640.50 | <0.0001 |